268 related articles for article (PubMed ID: 21366404)
1. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.
Wongthida P; Diaz RM; Pulido C; Rommelfanger D; Galivo F; Kaluza K; Kottke T; Thompson J; Melcher A; Vile R
Hum Gene Ther; 2011 Nov; 22(11):1343-53. PubMed ID: 21366404
[TBL] [Abstract][Full Text] [Related]
2. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.
Rommelfanger DM; Wongthida P; Diaz RM; Kaluza KM; Thompson JM; Kottke TJ; Vile RG
Cancer Res; 2012 Sep; 72(18):4753-64. PubMed ID: 22836753
[TBL] [Abstract][Full Text] [Related]
3. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
[TBL] [Abstract][Full Text] [Related]
4. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
[TBL] [Abstract][Full Text] [Related]
5. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.
Wongthida P; Diaz RM; Galivo F; Kottke T; Thompson J; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):150-8. PubMed ID: 20959810
[TBL] [Abstract][Full Text] [Related]
6. Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.
Leveille S; Goulet ML; Lichty BD; Hiscott J
J Virol; 2011 Dec; 85(23):12160-9. PubMed ID: 21917977
[TBL] [Abstract][Full Text] [Related]
7. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R
Gene Ther; 2010 Feb; 17(2):158-70. PubMed ID: 20016540
[TBL] [Abstract][Full Text] [Related]
8. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer.
Wongthida P; Diaz RM; Galivo F; Kottke T; Thompson J; Pulido J; Pavelko K; Pease L; Melcher A; Vile R
Cancer Res; 2010 Jun; 70(11):4539-49. PubMed ID: 20484025
[TBL] [Abstract][Full Text] [Related]
9. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.
Qiao J; Wang H; Kottke T; Diaz RM; Willmon C; Hudacek A; Thompson J; Parato K; Bell J; Naik J; Chester J; Selby P; Harrington K; Melcher A; Vile RG
Gene Ther; 2008 Apr; 15(8):604-16. PubMed ID: 18305577
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
11. Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy.
Blanchard M; Shim KG; Grams MP; Rajani K; Diaz RM; Furutani KM; Thompson J; Olivier KR; Park SS; Markovic SN; Pandha H; Melcher A; Harrington K; Zaidi S; Vile R
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):577-87. PubMed ID: 26461000
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
Diaz RM; Galivo F; Kottke T; Wongthida P; Qiao J; Thompson J; Valdes M; Barber G; Vile RG
Cancer Res; 2007 Mar; 67(6):2840-8. PubMed ID: 17363607
[TBL] [Abstract][Full Text] [Related]
13. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG
Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032
[TBL] [Abstract][Full Text] [Related]
14. Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.
Cockle JV; Rajani K; Zaidi S; Kottke T; Thompson J; Diaz RM; Shim K; Peterson T; Parney IF; Short S; Selby P; Ilett E; Melcher A; Vile R
Neuro Oncol; 2016 Apr; 18(4):518-27. PubMed ID: 26409567
[TBL] [Abstract][Full Text] [Related]
15. A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity.
Das K; Belnoue E; Rossi M; Hofer T; Danklmaier S; Nolden T; Schreiber LM; Angerer K; Kimpel J; Hoegler S; Spiesschaert B; Kenner L; von Laer D; Elbers K; Derouazi M; Wollmann G
Nat Commun; 2021 Aug; 12(1):5195. PubMed ID: 34465781
[TBL] [Abstract][Full Text] [Related]
16. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
[TBL] [Abstract][Full Text] [Related]
17. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.
Shim KG; Zaidi S; Thompson J; Kottke T; Evgin L; Rajani KR; Schuelke M; Driscoll CB; Huff A; Pulido JS; Vile RG
Mol Ther; 2017 Apr; 25(4):962-975. PubMed ID: 28237836
[TBL] [Abstract][Full Text] [Related]
19. Combination of virotherapy with VSV and tumor vaccination significantly enhances the efficacy of antitumor therapy.
Sobhanimonfared F; Bamdad T; Sadigh ZA; Nikoo HR; Choobin H
Acta Virol; 2018; 62(4):394-400. PubMed ID: 30472869
[TBL] [Abstract][Full Text] [Related]
20. The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.
Janelle V; Langlois MP; Lapierre P; Charpentier T; Poliquin L; Lamarre A
Mol Ther; 2014 Jun; 22(6):1198-1210. PubMed ID: 24590047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]